KRAS G12C

Clinical trials for KRAS G12C explained in plain language.

Never miss a new study

Get alerted when new KRAS G12C trials appear

Sign up with your email to follow new studies for KRAS G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 7 Not yet recruiting 1 Not yet finished but already full! 2 Completed 1

New Two-Pronged attack on Tough-to-Treat lung cancer

Disease control Not yet recruiting

This study is testing a new combination of two drugs, glecirasib and ivonescimab, for people with advanced non-small cell lung cancer who have a specific genetic change called KRAS G12C and have not yet received treatment. The main goals are to find the safest and most effective …

Matched conditions: KRAS G12C

Phase: PHASE1, PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control

Last updated Apr 01, 2026 22:56 UTC

KRAS G12C

Get alerted when new KRAS G12C trials appear

New Two-Pronged attack on Tough-to-Treat lung cancer